irinotecan acetate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: irinotecan acetate
• 英文别名: 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carboxyoxycamptothecin acetic acid salt；acetic acid;[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
• 化学式: C₂H₄O₂*C₃₃H₃₈N₄O₆
• 分子量: 646.74
• InChiKey: BEAUQMFZXZWKRD-WAQYZQTGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.18
• 重原子数：
  47
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  150
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  irinotecan acetate 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 盐酸伊立替康
  参考文献：
  名称：

  CRYSTALLINE IRINOTECAN HYDROCHLORIDE AND METHODS FOR ITS PREPARATION

  摘要：

  揭示了一种盐酸伊立替康（I）的结晶形式及其从粗制盐酸伊立替康或另一种多形态伊立替康制备的方法。该结晶形式特别适用于工业用途，因为易于过滤，并具有高稳定性和纯度特性。

  公开号：

  US20100179180A1

文献信息

• [EN] NOVEL POLYMORPH OF IRINOTECAN HYDROCHLORIDE<br/>[FR] NOUVEAU COMPOSÉ POLYMORPHE DU CHLORHYDRATE D'IRINOTÉCAN
  申请人：HETERO RESEARCH FOUNDATION

  公开号：WO2012007952A1

  公开（公告）日：2012-01-19

  The present invention provides a novel crystalline form of irinotecan hydrochloride, process for its preparation and pharmaceutical compositions comprising it. Thus, for example, irinotecan hydrochloride trihydrate was dissolved in a mixture of methanol and methylene dichloride, the solvent was distilled off and then added acetone, and stirred for 18 hour at room temperature, filtered and dried to obtain irinotecan hydrochloride crystalline form H1.

  本发明提供了一种新颖的伊立替康盐酸盐的晶体形式，其制备方法以及包括它的药物组合物。例如，伊立替康盐酸盐三水合物溶解在甲醇和二氯甲烷混合物中，溶剂蒸馏后加入丙酮，在室温下搅拌18小时，过滤并干燥即可得到伊立替康盐酸盐晶体形式H1。
• Novel crystal forms of irinotecan hydrochloride
  申请人：Chen Shu-Ping

  公开号：US20070072890A1

  公开（公告）日：2007-03-29

  The present invention provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating metastatic carcinoma of the colon or rectum using same.

  本发明提供了伊立替康盐酸盐的新型晶体形式及其制备方法，含有该新型晶体形式的制药组合物，以及使用它们治疗结肠或直肠转移性癌症的方法。
• ACID ADDITION SALT OF IRINOTECAN
  申请人：KABUSHIKI KAISHA YAKULT HONSHA

  公开号：EP1798235A1

  公开（公告）日：2007-06-20

  The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, citric acid, maleic acid, and succinic acid to irinotecan, to a method for producing the salt, and to a pharmaceutical composition containing the salt. The addition salt requires no heating process during drug preparation and provides an aqueous drug product in which the salt is stably dissolved.

  本发明涉及一种伊立替康酸加成盐，它是通过将选自硫酸、硝酸、磷酸、甲磺酸、柠檬酸、马来酸和琥珀酸组成的组中的一种酸加成到伊立替康中而形成的，本发明还涉及一种生产该盐的方法，以及一种含有该盐的药物组合物。这种添加盐在药物制备过程中不需要加热过程，并能提供一种盐能稳定溶解的水性药物产品。
• Novel crystal form of irinotecan hydrochloride
  申请人：Scinopharm Singapore Pte, Ltd.

  公开号：EP2082741A1

  公开（公告）日：2009-07-29

  The present invention provides for novel crystalline form of irinotecan hydrochloride and processes for their preparation, pharmaceutical compositions containing the novel form and methods for treating metastatic carcinoma of the colon or rectum using same.

  本发明提供了盐酸伊立替康的新型结晶形式及其制备工艺、含有该新型结晶形式的药物组合物以及使用该新型结晶形式治疗结肠或直肠转移性癌的方法。
• Polymorphism for irinotecan free base
  申请人：ScinoPharm Taiwan, Ltd.

  公开号：US10919905B2

  公开（公告）日：2021-02-16

  Crystalline form S1 of irinotecan free base characterized by a powder X-ray diffraction pattern with peaks at about 8.7±0.2, 13.1±0.2, 14.5±0.2, 17.4±0.2, 18.4±0.2, 20.9±0.2, 24.0±0.2 and 27.5±0.2 degrees two-theta degrees two-theta, and crystalline form S2 of irinotecan free base characterized by a powder X-ray diffraction pattern with peaks at about 7.1±0.2, 10.6±0.2, 12.4±0.2, 20.6±0.2, 21.6±0.2 and 24.2±0.2 degrees two-theta.

  伊立替康游离碱的结晶形式S1，其特征在于粉末X射线衍射图谱的峰值约为8.7±0.2、13.1±0.2、14.5±0.2、17.4±0.2、18.4±0.2、20.9±0.2、24.0±0.2和27.5±0.2。